Selected publications
-
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
Nature Medicine.
2015
Academic Article
GET IT
Times cited: 50 -
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Blood.
2015
Academic Article
GET IT
Times cited: 52 -
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
PLoS ONE.
2014
Academic Article
GET IT
Times cited: 17 -
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Nature.
2012
Academic Article
GET IT
Times cited: 204 -
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood.
2009
Academic Article
GET IT
Times cited: 465 -
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms.
Nature Genetics.
2009
Academic Article
GET IT
Times cited: 234